Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K
Antibody Structure01:10

Antibody Structure

65.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.9K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

8.5K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative plastid genomics of Gastrochilus (Orchidaceae) with insights into molecular markers and phylogeny.

BMC genomics·2026
Same author

An update on patent issues regarding antibody-drug conjugates.

Nature biotechnology·2026
Same author

The complex patent situation regarding antibody Fc engineering.

Journal of biotechnology·2026
Same author

The CRISPR Cas patent files, part 4: All back to zero, think again!

Journal of biotechnology·2025
Same author

Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine.

Cell reports·2025
Same author

The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variants.

Journal of biotechnology·2025

Related Experiment Video

Updated: Feb 19, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.1K

Enhancing antibody patent protection using epitope mapping information.

Xiaoxiang Deng1, Ulrich Storz2, Benjamin J Doranz1

  • 1a Integral Molecular , Philadelphia , PA , USA.

Mabs
|November 10, 2017
PubMed
Summary

Therapeutic monoclonal antibody (mAb) patent protection is strengthened by precise epitope mapping. Detailed epitope data, including amino acid resolution, is crucial for patent novelty, enforceability, and freedom-to-operate in the growing mAb market.

Keywords:
epitope mappingintellectual propertymonoclonal antibodynon-obviousnessnoveltypatentwritten description

More Related Videos

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.6K
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

7.4K

Related Experiment Videos

Last Updated: Feb 19, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.1K
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

15.6K
Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein
08:04

Overlapping Peptide Library to Map Qa-1 Epitopes in a Protein

Published on: December 20, 2017

7.4K

Area of Science:

  • Biotechnology
  • Intellectual Property Law
  • Immunology

Background:

  • The global therapeutic monoclonal antibody (mAb) market exceeds $100 billion, necessitating robust patent protection.
  • Developers face increasing challenges in securing and enforcing patents for therapeutic mAbs.
  • Evolving patent law requires strategic use of scientific data for strong intellectual property claims.

Purpose of the Study:

  • To review best practices for utilizing epitope information to enhance mAb patent protection.
  • To analyze how epitope data influences patent novelty, non-obviousness, and written description requirements.
  • To demonstrate the role of epitope mapping in achieving freedom-to-operate for next-generation mAbs.

Main Methods:

  • Review of current patent law landscape and high-profile court cases involving mAb patents.
  • Analysis of strategies for using epitope binding site data in patent applications.
  • Examination of the impact of epitope data quality, conformation, and resolution on patent breadth and strength.

Main Results:

  • Epitope mapping claims are central to mAb patent litigation, as seen in cases like Amgen v. Sanofi.
  • Successful epitope mapping claims require describing multiple mAbs sharing an epitope at amino acid resolution.
  • High-quality, high-resolution epitope data is essential for broad and strong mAb patent rights.

Conclusions:

  • Precise epitope information is critical for strengthening patent protection and enforceability of therapeutic mAbs.
  • Strategic use of detailed epitope data can overcome challenges in patenting broad genus antibody claims.
  • Understanding epitope characteristics is key to navigating freedom-to-operate and differentiating products in the competitive mAb market.